Recent development of gold(i) and gold(iii) complexes as therapeutic agents for cancer diseases. (14th June 2022)

• Record Type: Journal Article
• Authors: Lu, Yunlong; Ma, Xiaoyan; Chang, Xingyu; Liang, Zhenlin; Lv, Lin; Shan, Min; Lu, Qiuyue; Wen, Zhenfan; Gust, Ronald; Liu, Wukun
• Is Part Of: Chemical Society reviews. Volume 51:Number 13(2022)
• Page Start: 5518
• Page End: 5556
• Publication Date: 2022-06-14
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1039/d1cs00933h
• Languages: English
• ISSNs: 0306-0012

Abstract

Abstract : In this review, the recent progress in gold(i ) and gold(iii ) complexes are comprehensively summarized, and their anti-cancer activity and mechanism of action are documented. Abstract : Metal complexes have demonstrated significant antitumor activities and platinum complexes are well established in the clinical application of cancer chemotherapy. However, the platinum-based treatment of different types of cancers is massively hampered by severe side effects and resistance development. Consequently, the development of novel metal-based drugs with different mechanism of action and pharmaceutical profile attracts modern medicinal chemists to design and synthesize novel metal-based agents. Among non-platinum anticancer drugs, gold complexes have gained considerable attention due to their significant antiproliferative potency and efficacy. In most situations, the gold complexes exhibit anticancer activities by targeting thioredoxin reductase (TrxR) or other thiol-rich proteins and enzymes and trigger cell death via reactive oxygen species (ROS). Interestingly, gold complexes were recently reported to elicit biochemical hallmarks of immunogenic cell death (ICD) as an ICD inducer. In this review, the recent progress of gold(i ) and gold(iii ) complexes is comprehensively summarized, and their activities and mechanism of action are documented.